Recombinant Human IFN-α2 (ELISA Std.)

Pricing & Availability
Regulatory Status
Other Names
IFN-alpha 2B, IFN-alphaA, IFNA2, IFNA2B, Interferon Alpha 2
Ave. Rating
Submit a Review
Product Citations
Coating Buffer B, M4509E12 at 4 µg/mL as capture antibody, Blocked Assay Diluent A (ADA) 1 hr, lyophilized standard 2 hr in Assay Buffer G 50:50 with Matrix A run 12.5 – 800 pg/mL, BL25372 (MT-2) at 0.1 µg/mL 1 hr for detection in ADA, 0.8 µg/mL Avidin HRP in ADA 30 min, TMB F 15 min (in house 76335).
  • RECOM_HU_IFN-a2_ELISA_STD_122618
    Coating Buffer B, M4509E12 at 4 µg/mL as capture antibody, Blocked Assay Diluent A (ADA) 1 hr, lyophilized standard 2 hr in Assay Buffer G 50:50 with Matrix A run 12.5 – 800 pg/mL, BL25372 (MT-2) at 0.1 µg/mL 1 hr for detection in ADA, 0.8 µg/mL Avidin HRP in ADA 30 min, TMB F 15 min (in house 76335).
Cat # Size Price Quantity Avail. Save
592709 4 pack 64€
Check Availability

Need larger quantities of this item?
Request Bulk Quote

Interferons are divided into type I, II, and III. Type I IFNs (IFN-α and IFN-β) are most abundant in number, distribution, and expression. Also, they are highly conserved among mammals in both structure and function. IFN-α2 has been used in the treatment of cancer such as bladder cancer, hepatocellular carcinoma, and leukemia. IFN-α2 augments the suppressed immune functions in patients with head and neck squamous cell carcinoma (HNSCC). IFN-α2 initiated T and NK cell mediated cytotoxicity of tumor cells through IFNγ dependent and independent mechanisms. IFN-α2 enhances suppressed T cell cytotoxicity by stimulation of the perforin-granzyme B system (IFNγ dependent). Also, IFN-α2 induces the expression of perforin-granzyme B in NK cells (NK mediated cytotoxicity, IFNγ independent). In a preliminary study, IFN-α2 appears to be an effective immunostimulator and impacts the clinical outcome in tongue squamous cell carcinoma patients. IFN-α had been used in the treatment of chronic hepatitis C (CHC); nevertheless, IFN-α is relatively unstable and requires frequent parenteral administration. Pegylation of IFN-α, polyethylene glycol (PEG)-IFN-α, reduces in vitro activity but increase the stability and plasma half-life of IFN-α; therefore, PEG-IFN-α has replaced IFN-α in CHC treatment.

Product Details
Technical Data Sheet (pdf)

Product Details

Human IFN-α2, amino acids Cys24-Glu188 (Accession# NM_000605) was expressed in E.coli.
Molecular Mass
The 166 amino acid recombinant protein has a predicted molecular mass of approximately 19.4 kD. The DTT-reduced and non-reduced proteins migrate at approximately 20 kD and 18 kD respectively by SDS-PAGE. The N-terminal amino acid is Met
>95%, as determined by Coomassie stained SDS-PAGE.
Lyophilized in sterile-filtered PBS, pH 7.2, containing 1% BSA, 0.09% sodium azide, and protease inhibitors
Lot-specific (please contact technical support for mass/vial, or use our Lookup tool if you have a lot number.)
Storage & Handling
Immediately upon receipt, store unopened vials between 2°C and 8°C and use within 12 months from date of receipt. Prior to use, reconstitute the lyophilized powder with 0.2 ml of PBS containing a carrier protein (e.g., 1% BSA, protease free), pH 7.4. Re-cap vial, vortex. Allow the reconstituted standard to sit at room temperature for 15 minutes, vortex again to mix completely. The reconstituted standard stock solution can be aliquoted into polypropylene vials and stored at -70°C for up to one month. Do not re-use diluted standards. Use a manual defrost freezer and avoid repeated freeze thaw cycles.


Recommended Usage

Each lot of this protein is quality control tested by ELISA assay. For use as an ELISA standard, a standard curve comprised of doubling dilutions from 800 to 12.5 pg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

This IFN-a2 protein is useful as a standard for a human IFN-a2 sandwich ELISA, using unlabeled M4509E12 antibody (Cat. No. 537102) as capture and biotinylated BL25372 antibody (Cat. No. 537204) as detection.

Antigen Details


IFN-α is ubiquitously expressed.

IFN-α stimulates cytotoxic T lymphocytes and natural killer cell function. IFN-α has immunomodulatory and antiviral properties. IFNα2a induces CXCL10 in human microvascular endothelial cells and pulmonary artery smooth muscle cells. It is induced by viral infection.
A variety of cells express the IFNα receptor (IFNAR).
IFNAR complex has two components, IFNAR1 and IFNAR2.
Biology Area
Immunology, Innate Immunity
Molecular Family
Antigen References
  1. Bose A and Baral R. 2007. Immunol Lett. 108:68.
  2. Zhao W, et al. 2008. J Immunol. 180:5483.
  3. Badiger R, et al. 2012. Plos One. 7:e46779.
  4. Aghemo A, et al. 2010. Nat Rev Gastroenterol Hepatol. 7:485.
  5. Becker-Merok A, et al. 2013. Lupus. 22:155.
  6. Mukherjee KK, et al. 2012. Indian J Med Res. 136:54
Gene ID
3440 View all products for this Gene ID
View information about IFN-a2 on

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 12/26/2018

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Insert Note Here
Save Close Clear
Lab Timer
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account